β2-adrenergic signalling promotes cell migration by upregulating expression of the metastasis-associated molecule LYPD3 by Gruet, M et al.
biology
Article
β2-Adrenergic Signalling Promotes Cell Migration by
Upregulating Expression of the Metastasis-Associated
Molecule LYPD3
Michael Gruet 1,†, Daniel Cotton 1,2,†, Clare Coveney 1, David J. Boocock 1 , Sarah Wagner 1,
Lucie Komorowski 1, Robert C. Rees 1, A. Graham Pockley 1, A. Christopher Garner 2,
John D. Wallis 2, Amanda K. Miles 1,*,† and Desmond G. Powe 1,3,†
1 John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham NG11 8NS, UK;
michaelgruet@hotmail.co.uk (M.G.); Daniel_Cotton@hotmail.co.uk (D.C.); Clare.Coveney@ntu.ac.uk (C.C.);
david.boocock@ntu.ac.uk (D.J.B.); sarah.wagner@ntu.ac.uk (S.W.); lucie.komorowski@gmail.com (L.K.);
robert.rees@ntu.ac.uk (R.C.R.); graham.pockley@ntu.ac.uk (A.G.P.); des.powe@talktalk.net (D.G.P.)
2 School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK;
christopher.garner@ntu.ac.uk (A.C.G.); john.wallis@ntu.ac.uk (J.D.W.)
3 Department of Cellular Pathology, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust,
Derby Road, Nottingham NG7 2UH, UK
* Correspondence: amandakcartwright1978@gmail.com; Tel.: +44-(0)115-848-3754
† These authors contributed equally.
Received: 13 January 2020; Accepted: 20 February 2020; Published: 22 February 2020


Abstract: Metastasis is associated with poor prognosis in breast cancer. Although some studies
suggest beta-blockers increase survival by delaying metastasis, others have been discordant. This
study provides both insights into the anomalous findings and identifies potential biomarkers that
may be treatment targets. Cell line models of basal-type and oestrogen receptor-positive breast cancer
were profiled for basal levels of adrenoceptor gene/protein expression, and β2-adrenoceptor mediated
cell behaviour including migration, invasion, adhesion, and survival in response to adrenoceptor
agonist/antagonist treatment. Protein profiling and histology identified biomarkers and drug targets.
Baseline levels of adrenoceptor gene expression are higher in basal-type rather than oestrogen
receptor-positive cancer cells. Norepinephrine (NE) treatment increased invasive capacity in all cell
lines but did not increase proliferation/survival. Protein profiling revealed the upregulation of the
pro-metastatic gene Ly6/PLAUR Domain-Containing Protein 3 (LYPD3) in norepinephrine-treated
MDA-MB-468 cells. Histology confirmed selective LYPD3 expression in primary and metastatic breast
tumour samples. These findings demonstrate that basal-type cancer cells show a more aggressive
adrenoceptor-β2-activated phenotype in the resting and stimulated state, which is attenuated by
adrenoceptor-β2 inhibition. This study also highlights the first association between ADRβ2 signalling
and LYPD3; its knockdown significantly reduced the basal and norepinephrine-induced activity of
MCF-7 cells in vitro. The regulation of ADRβ2 signalling by LYPD3 and its metastasis promoting
activities, reveal LYPD3 as a promising therapeutic target in the treatment of breast and other cancers.
Keywords: breast cancer; β2-adrenoceptor; beta-blockers; LYPD3
1. Introduction
Metastasis is critical in the progression of breast cancer and is frequently associated with poor
prognosis. Although strategies that inhibit metastasis will increase progression-free survival (PFS),
the identification of therapeutic druggable targets that prevent metastasis remain in its infancy [1].
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Approaches for preventing metastasis require drugs that have cytostatic rather than cytotoxic properties,
and are principally aimed at suppressing progression along the multistep metastasis pathway [2].
The repurposing of beta-adrenergic receptor antagonists (beta-blockers) as an adjuvant therapy for
the treatment of breast cancer has been proposed on the basis of their anti-metastatic properties [3–5].
In vitro and in vivo models have demonstrated propranolol-induced inhibition of cancer cell signalling
pathways decreases cell adhesion, migration, invasion, extravasation and colonisation in distant tissues
including bone [6–8], thereby leading to reduced metastasis [9]. These pathways are triggered by
catecholamine hormones such as norepinephrine acting on beta (β-) adrenergic G-protein coupled
receptors (GPCR) expressed on breast cancer cells. Epidemiology studies observing the therapeutic
potential of beta-blockers for treating breast cancer have revealed an association between (coincidental)
beta-blocker usage and survival benefits [10–12]. The clinical evaluation of propranolol as a neoadjuvant
or perioperative treatment for breast cancer is on-going [13–16]. However, a recent contradictory
study has reported no benefit between prescribed beta-blockers and survival [17], whereas a different
study using the basal-type MDA-MB-231 breast cancer cell line model showed that beta-adrenergic
receptor (ADRβ2) agonism (rather than antagonism) inhibited tumour proliferation [18]. Further
studies are required to explain these discordant findings, which could result from variance in (a) in vitro
cell line models; (b) patient cohort selected in pre-clinical studies; (c) pharmacologic selectivity of
prescribed beta-blockers.
In this study, adrenoceptor expression and β2-adrenoceptor-mediated metastasis-associated
cell behaviour were examined in three frequently used in vitro cell line models of ‘stress-induced’
triple-negative basal-type breast cancer and compared to a popular oestrogen-positive cell line model.
β2-adrenoceptor-induced proteomic changes were assessed to better understand ADR-mediated cancer
pathways, and provide biomarker and therapeutic treatment target identification. The study reveals
complex and distinct differences between the cell lines and also identified a link between ADRβ2
signalling and LYPD3; revealing LYPD3 as a potential key mediator in ADRβ2 driven metastasis.
2. Results
2.1. Basal-Type Breast Cancer Cell Lines Express Higher Levels of Functional β2-Adrenoceptor and Their
Survival Is Not Significantly Altered Following Non-Selective ADRβ Activation
The steady state mRNA expression of each ADR subtype was assessed in unstimulated breast
cancer cell lines. β2-adrenoceptor gene expression was highest in the unstimulated MDA-MB-231
basal cell line, followed by MDA-MB-468 and BT-549. Negligible expression was observed in the
ER-positive MCF-7 cell line (Figure 1A). To evaluate the cell surface expression of the selected ADRs,
flow cytometry was performed. The level of membranous ADRβ2 expression was highest in the
unstimulated basal cell line MDA-MB-468 although levels were very similar between this cell line
and MDA-MB-231 and MCF-7. BT-549 cells expressed the lowest levels of ADRβ2 (Figure 1B).
These results show that the cell lines, in our hands, express ADRs at both the mRNA and protein
levels. All cell lines treated with the non-selective ADRβ agonist isoproterenol showed elevated
accumulation of intracellular cAMP (MDA-MB-231 > MDA-MB-468 > BT-549 > MCF-7) (Figure 1C),
confirming functional ADR. Furthermore, simultaneous treatment with norepinephrine and the ADRβ2
selective antagonist ICI-118,551 had no significant effect on cell survival at therapeutically relevant
concentrations compared to treatment of the cells with norepinephrine alone (Supplementary Materials
Figure S1). These results demonstrate that any change in cell migration/invasion observed following
ADR agonism/antagonism is not due to the compounds affecting cell survival.
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Figure 1. Adrenoceptor (ADR) expression on breast cancer cells and measurement of cAMP (cyclic 
adenosine monophosphate) levels following adrenergic stimulation. (A) Relative expression of ADR 
mRNA in breast cancer cell lines was quantified by qRT-PCR (quantitative reverse transcription 
polymerase chain reaction) and relative expression (2−ΔΔCT) was determined by normalisation to 
housekeeping genes. β2-adrenoceptor gene expression was strongest in the basal-type cell lines MDA-
MB-231 and MDA-MB-468. (B) Expression of the adrenoceptors on unpermeabilised breast cancer 
cells was assessed by measuring median fluorescence intensity (MFI) using flow cytometry. 
Membranous β2-adrenoceptor protein expression was highest in the basal-type cell line MDA-MB-
468, followed by MDA-MB-231 > MCF-7 > BT-549. (C) Isoproterenol (β-agonist) stimulated cAMP 
accumulation in breast cancer cell lines. Cells were treated in the presence of IBMX to prevent cAMP 
degradation. cAMP production was highest in the order MDA-MB-231 > MDA-MB-468 > BT-549 > 
MCF-7. All assays were performed in triplicate (n = 3). Results shown are the mean ± standard 
deviation. 
Figure 1. Adrenoc ptor (ADR) expression on breast ca cer cells and measurement of cAMP (cyclic
adenosine monophosphate) levels following adrenergic stimulation. (A) Relative expression of ADR
mRNA in breast cancer cell lines was quantified by qRT-PCR (quantitative reverse transcription
polymerase chain reaction) and relative expression (2−∆∆CT) was determined by normalisation to
housekeeping genes. β2-adrenoceptor gene expression was strongest in the basal-type cell lines
MDA-MB-231 and MDA-MB-468. (B) Expression of the adrenoceptors on unpermeabilised breast
cancer cells was assessed by measuring median fluorescence intensity (MFI) using flow cytometry.
Membranous β2-adrenoceptor protein expression was highest in the basal-type cell line MDA-MB-468,
followed by MDA-MB-231 > MCF-7 > BT-549. (C) Isoproterenol (β-agonist) stimulated cAMP
accumulation in breast cancer cell lines. Cells were treated in the presence of IBMX to prevent
cAMP degradation. cAMP production was highest in the order MDA-MB-231 > MDA-MB-468 >
BT-549 > MCF-7. All assays were performed in triplicate (n = 3). Results shown are the mean ±
standard deviation.
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2.2. Substrate-Modulated Cell Adhesion/Migration/Invasion Responses Are ADRβ-Dependent
The ability of ADR agonist and antagonist compounds to modulate different parameters associated
with metastasis were assessed.
2.2.1. Cell Adhesion
Cell-cell and cell-substrate adhesion characteristics play a pivotal role in many of the key steps
of the metastatic cascade and in the metastatic cascade, cells alter their adhesive capacity during
transmigration, intravasation and extravasation. The observed increases in adhesive capacity induced
by norepinephrine and isoproterenol are mediated by the β1-integrins. Strell et al. also concluded that
two possible routes of treatment for the inhibition of MDA-MB-231 cell adhesion to lung epithelial
cells is to either block β2-adrenoceptor signalling or to block the action of the β1-integrins [7].
Although the use of tissue culture plastic can provide an insight into the adhesive capacity of cells,
its use does not appropriately reflect the extracellular matrix proteins that make up the surfaces of the
tumour microenvironment and other important areas of the body that cells may encounter during the
metastatic cascade. Fibronectin, vitronectin and collagen I are among the most abundant extracellular
matrix proteins and are among the key ligands of the crucial adhesion-regulating integrins, therefore,
the influence norepinephrine has on breast cancer cells adhering to these substrates was investigated.
Simultaneous treatment with norepinephrine and the ADRβ selective antagonist ICI-118,551
reduced the adhesion in all four cell lines grown on collagen I and vitronectin coated surfaces (p < 0.05).
The adhesion of the basal-type MDA-MB-468 and MDA-MB-231 cell lines to fibronectin-coated surfaces
was also reduced (p < 0.01) (Figure 2A and Supplementary Materials Figure S2). These results indicate
that the adhesion of breast cancer cells can vary according to the surface on which they are grown.
2.2.2. Cell Migration
The ADRβ selective antagonist ICI-118,551 completely abrogated the enhanced migration of
MDA-MB-468, BT-549 and MCF-7 cells induced by norepinephrine treatment, as assessed using
scratch migration assays (Supplementary Materials Figure S3). When the migration of cells through
an 8 µm porous membrane was assessed, norepinephrine caused a significant increase in the migration
of MDA-MB-468 cells (p < 0.01) and this increase was completely reversed by the concomitant
administration of ICI-118,551 (p < 0.01) (Figure 2B). Interestingly, norepinephrine treatment significantly
reduced the migration of MDA-MB-231 cells when grown on both uncoated plastic (Supplementary
Materials Figure S3) and when migrating through a porous membrane (p < 0.01) (Figure 2B). Treatment
with ICI-118,551 alone reduced migration, albeit non-significantly (Figure 2B). Whilst there was
an increase in migration of BT-549 and MCF-7 cells following norepinephrine stimulation and
a subsequent decrease following concomitant ICI-118,551 administration, this was not statistically
significant. These observations were confirmed and were statistically significant in our scratch assay
data (Supplementary Materials Figure S3), which leads us to believe that this technique for measuring
cell migration may not be the best method for every cell line. These findings reinforce the need for
investigating the invasive behaviour of cells using a more biologically relevant model and whilst
in vivo models would answer these questions, it is important to try and identify a relevant in vitro
model before animal models are used.
2.2.3. Cell Invasion
Norepinephrine stimulation alone significantly increased the invasive capacity of all breast cancer
cell lines through a basement protein-coated membrane (p < 0.05). Furthermore, treatment with the
ICI-118,551 antagonist significantly decreased the invasive capacity of MDA-MB-468, MDA-MB-231,
BT-549 and MCF-7 cell lines (p < 0.05) (Figure 2C), suggesting that our cell line models are able to
recapitulate what others in the literature have observed and provide a sound model to investigate
proteomic changes following ADR agonism/antagonism [19].
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cancer cell adhesion, migration and invasion in vitro. (A) β2-adrenoceptor blockade using ICI-118,551 
inhibits norepinephrine-induced adhesion of breast cancer cells to fibronectin and collagen I in vitro. 
Quantitative analysis of the number of cells adhered to wells coated with 10 µg/mL of fibronectin, 
collagen I or vitronectin after 3 h of incubation. Simultaneous treatment with norepinephrine and the 
selective antagonist ICI-118,551 compound reduced the adhesion in all four cell lines grown on 
Figure 2. Effect of norepinephrine and the selective β2-adrenoceptor antagonist ICI-118,551 on breast
cancer cell adhesion, migration and invasion in vitro. (A) β2-adrenoceptor blockade using ICI-118,551
inhibits norepinephrine-induced adhesion of breast canc r cells to fibronectin and collagen I in vitro.
Quantitative analysis of the number of cells adhered to wells coated with 10 µg/mL of fibronectin,
collagen I or vitronectin after 3 h of incubation. Simultaneous treatment with norepinephrine and the
selective antagonist ICI-118,551 compound reduced the adhesion in all four cell lines grown on collagen
I and vitronectin coated surfaces (p < 0.05). Only the basal-type MDA-MB-468 and MDA-MB-231
cell lines showed a reduction in cell adhesion when grown on fibronectin (p < 0.01). (B) Quantitative
analysis of the influence of ICI-118,551 treatment on the transwell migration of the breast cancer cell
lines. Norepinephrine challenge caused a significant increase in the migration of MDA-MB-468 cells
(p < 0.05) and this increase was completely reversed by the concomitant administration of ICI-118,551
antagonist (p < 0.05). (C) Quantitative analysis of the influence of ICI-118,551 treatment on the invasion
of the breast cancer cell line through a basement membrane epithelium (BME) coated membrane.
Treatment with the ICI-118,551 antagonist significantly decreased the invasive capacity of MDA-MB-468,
MDA-MB-231 and MCF-7 cell lines following norepinephrine challenge (p < 0.05). All assays were
performed in triplicate (n = 3). Results shown are the mean± standard deviation. Statistical analysis was
performed using a one-way ANOVA (analysis of variance) test (Dunnett’s multiple comparison test).
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2.3. Protein Expression Changes in MDA-MB-468 and MDA-MB-231 Cells
To further investigate the potential role of the ADRβ2 in breast cancer cell migration, we
performed mass spectrometry analyses of protein extracts taken from the lysate and media (secretome)
of MDA-MB-468 and MDA-MB-231 cells treated with norepinephrine, isoproterenol and ICI-118,551
(Supplementary Materials Table S4). These cell lines were chosen for the following reasons: increased
levels of ADRβ2 mRNA expression, the cells displayed opposing effects following norepinephrine
stimulation and the cell lines were derived from the triple negative phenotype, which is of importance
for developing new potential treatment regimens or repurposing current therapeutics. Differentially
expressed proteins for MDA-MB-468 and MDA-MB-231 cells secretome and lysate are shown in Tables 1
and 2. One thousand one hundred and sixty eight (MDA-MB-468 secretome), 2715 (MDA-MB-468
lysate), 2635 (MDA-MB-231 secretome) and 3117 (MDA-MB-231 lysate) proteins were quantified by
SWATH-MS (Sequential Window Acquisition of All Theoretical Mass Spectra – Mass Spectrometry) and
processed using OneOmics (Sciex, Framingham, MA, USA). The analysis revealed several differentially
expressed proteins within each cell line; however, the similarity between the cell lines in terms of shared
proteins was minimal with the following shared proteins only observed in the norepinephrine and
ICI-118,551 treated cells; H4 (P02805) and TSP (P07996). This is not unsurprising given the differences
in magnitude of response following stimulation of these cells with ADR agonists/antagonists.
Table 1. Differentially expressed proteins identified using SWATH (Sequential Window Acquisition
of All Theoretical Mass Spectra) MS (mass spectrometry) analysis of MDA-MB-468 cell lysate and
secretome following adrenoceptor agonism/antagonism.
Lysate Secretome
Treatment (vs UT) Protein Swiss-Prot ID Log2 Fold Change Protein SwissProt ID Log2 Fold Change
NE
LYPD3 O95274 2.235 IF5A1 P63241 2.181
CRYAB P02511 1.342 H2BFS P57053 2.066
NDRG1 Q92597 1.021 LYPD3 O95274 1.577
CASPE P31944 1.015 H4 P62805 1.489
AATM P10809 −1.010 STC1 P52823 1.077
CH60 P10809 −1.141 LIF P15018 −2.090
HINT2 Q9BX68 −1.206
MDHM P40926 −1.315
ECH1 Q13011 −1.431
H14 P10412 −1.515
ODO4 P36957 −1.520
H12 P16403 −1.574
ISO
IF172 Q9UG01 2.684 DPY30 Q9C005 1.320
LYPD3 O95274 2.564 ADML P35318 1.142
CRYAB P02511 1.413 H4 P62805 1.078
ANXA1 P04083 1.065
CTGF P29279 −1.151
UBA3 Q8TBC4 −1.995
LAMC1 P11047 −3.499
ICI 118,551
S10-A7 P31151 1.271 NDKA P15531 3.784
IF5A1 P63241 2.252
S10A6 P06703 1.651
ANXA2 P07355 1.311
DPY30 Q9C005 1.286
EDF1 O60869 −2.432
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Table 1. Cont.
Lysate Secretome
Treatment (vs UT) Protein Swiss-Prot ID Log2 Fold Change Protein SwissProt ID Log2 Fold Change
ICI 118,551 + NE
KRT36 O76013 2.160 CRK P46108 2.591
CRYAB P62750 1.776 NUCL P19338 1.947
NDRG1 P02768 −1.067 HS90A P07900 1.887
APOA1 P02647 1.769
ANXA2 P07355 1.694
CUTA O60888 1.642
STC1 P52823 1.474
FETUA P02765 1.418
LYPD3 O95274 1.308
H4 P62805 1.140
S100P P25815 1.139
SFRP1 Q8N474 1.136
TSP1 P07996 −1.280
EDF1 O60869 −4.362
BSSP4 Q0GZN4 −4.870
Log2 fold change represents the increase/decrease in protein expression relative to untreated samples (UT). Proteins
with a Log2 fold change of <1.0 or >1.0 and OneOmics confidence of ≥60% are shown. Proteins with single peptides
are excluded. Data is from six biological replicates. NE—norepinephrine, ISO—isoproterenol, UT—untreated.
Table 2. Differentially expressed proteins identified using SWATH MS analysis of MDA-MB-231 cell
lysate and secretome following adrenoceptor agonism/antagonism.
Lysate Secretome
Treatment (vs UT) Protein Swiss-Prot ID Log2 Fold Change Protein Swiss-Prot ID Log2 Fold Change
NE
No significantly changed proteins STC1 P52823 1.385
PPI1A P62937 1.106
CSF1 P09603 −1.025
B2MG P61769 −1.145
LFNG Q8NES3 −1.146
PTX3 P26022 −1.151
CUL5 Q93034 −1.160
HUWE1 Q7Z6Z7 −1.172
ANR28 O15084 −1.226
UROK P00749 −1.364
ITIH2 P19823 −1.383
CTGF P29279 −1.443
TSP1 P07996 −1.461
KI13B Q9NQT8 −2.489
ISO
G45IP Q8TAE8 3.552 STC1 P52823 1.097
ODBA P12694 3.331 KI13B Q9NQT8 −1.048
BAF O75531 −1.013 PPT1 P50897 −1.062
DBNL Q9UJU6 −1.025 CAD11 P55287 −1.088
S10A4 P26447 −1.037 CSF1 P09603 −1.109
THIO P10599 −1.074 HUWE1 Q7Z6Z7 −1.164
NEDD8 Q15843 −1.117 TSP1 P07996 −1.219
ANXA2 P07355 −1.129 CTGF P29279 −1.446
CYTB P04080 −1.171 UROK P00749 −1.564
PEBP1 P30086 −1.240 CATD P07339 −2.309
PRDX3 P30048 −1.273 ANR28 O15084 −2.313
LEG1 P09382 −1.329
GLRX3 O76003 −1.526
ANXA5 P08758 −2.254
TGM2 P21980 −4.288
ICI 118,551
GLSK O94925 1.757 HUWE1 Q7Z6Z7 −1.053
2A5E Q16537 1.179 ANR28 O15084 −1.581
LEG1 P09382 −1.017
PRDX3 P30048 −1.027
ANX11 P50995 −1.097
OST48 P39656 −1.141
ANXA2 P07355 −1.491
CALX P27824 −1.565
S10AA P60903 −1.615
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Table 2. Cont.
Lysate Secretome
Treatment (vs UT) Protein Swiss-Prot ID Log2 Fold Change Protein Swiss-Prot ID Log2 Fold Change
ANXA4 P09525 −1.670
PEBP1 P30086 −1.788
GALT2 Q10471 −1.927
DNJA2 O60884 −2.297
CP1B1 Q16678 −3.311
ICI 118,551 + NE
ODBA P12694 3.341 RLA2 P62805 1.019
S10AA P60903 −1.077 CUL5 Q93034 −1.049
ANX11 P50995 −1.223 H4 P62805 −1.071
ANXA2 P07355 −1.460 TCRG1 O14776 −1.078
ANXA4 P09525 −1.779 BGH3 Q15582 −1.079
CP013 Q96S19 −2.699 PPT1 P50897 −1.175
CYTS P01037 −1.180
TSP1 P07996 −1.230
CYTN P01037 −1.298
SRPX P78539 −1.345
HUWE1 Q7Z6Z7 −1.454
ITIH2 P19823 −1.509
FINC P02751 −1.510
ANR28 O15084 −1.930
KI13B Q9NQT8 −2.080
Log2 fold change represents the increase/decrease in protein expression relative to untreated samples (UT). Proteins
with a Log2 fold change of <1.0 or >1.0 and OneOmics confidence of ≥60% are shown. Proteins with single peptides
are excluded. Data is from six biological replicates. NE—norepinephrine, ISO—isoproterenol, UT—untreated.
Of significant interest was one protein, LYPD3, whose increased levels were found in the lysate
(2.235 fold change) and secretome (1.577 fold change) of MDA-MB-468 cells following norepinephrine
treatment (Table 1, Supplementary Materials Figure S4A) and in the lysate of MDA-MB-468 isoproterenol
treated cells (Table 1 and Supplementary Materials Figure S4B). Concomitant treatment with
norepinephrine and ICI-118,551 produced a smaller increase in LYPD3 levels in the secretome
of MDA-MB-468 (1.308 fold change) cells compared to norepinephrine stimulation alone (Table 1).
2.4. Increased LYPD3 Protein Is Exclusively Expressed in Primary and Metastatic Breast Cancer
The association between LYPD3 protein expression with tumour malignancy, patient age, tumour
grade and stage, TNM, oestrogen receptor and HER2 status are shown in Table 3. LYPD3 protein
staining was localised in the cytoplasm of breast adenocarcinoma cells, with occasional intense staining
in cellular membranes (Figure 3A). LYPD3 protein expression was exclusively localised in primary
(13.1% positive) and metastatic (17% positive) breast adenocarcinoma tissues, with no difference
between the two groups (p = 0.171). LYPD3 protein was not localised in adjacent normal breast tissue.
In further analyses, the malignant and metastatic cases were combined and compared to adjacent
normal breast cases. LYPD3 expression was decreased in low stage breast cancer lesions (stage I)
(p = 0.028) and was observed in low grade lesions, but the latter did not reach significance. There was
no significant association between LYPD3 and age, oestrogen receptor or HER2 status.
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Table 3. Clinical details of cases histologically assessed for LYPD3 protein expression was compared in
malignant (primary and metastatic) breast adenocarcinoma tissue.
LYPD3 Score
Negative Positive Chi Square (p-Value)
Age
<40 55 (91.7%) 5 (8.3%) 2.885 (0.236)
40–59 179 (84.8%) 32 (15.2%)
>60 43 (91.5%) 4 (8.5%)
Tumour Grade
1 39 (14.1%) 2 (4.9%) 10.034 (0.074)
1–2 4 (1.4%) 1 (2.4%)
2 105 (37.9%) 19 (46.3%)
2–3 0 (0) 1 (2.4%)
3 64 (23.1%) 9 (22%)
Tumour stage
I 18 (6.5%) 2 (4.9%) 15.712 (0.028)
IIA 102 (36.8%) 8 (19.5%)
IIB 32 (11.6%) 4 (9.8%)
IIIA 5 (1.8%) 3 (7.3%)
IIIB 19 (6.9%) 3 (7.3%)
IV 5 (1.8%) 1 (2.4%)
Oestrogen receptor status
Negative 137 (69.2%) 16 (76.2%) 0.442 (0.506)
Positive 61 (30.8%) 5 (23.8%)
HER2 status
Negative 162 (81.4%) 14 (66.7%) 2.580 (0.108)
Positive 37 (18.6%) 7 (33.3%)
Tissue pathology status
Malignant primary breast tumour 219 (86.9%) 33 (13.1%) 3.535 (0.171)
Metastasis 39 (83%) 8 (17%)
Adjacent normal breast tissue 19 (100%) 0 (0%)
Significant values are shown in bold and missing data censored.
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(right hand panel) of MDA-MB-468 cells following treatment demonstrated an upregulation of 
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Figure 3. LYPD3 expression in breast patient TMAs (tumour micro arrays), breast cancer cell lines and
a normal tissue RNA panel and the effects of LYPD3 gene knockdown. (A) IHC (immunohistochemistry)
staining of LYPD3 in (top left) normal breast, (top right) invasive ductal carcinoma (TN, grade 3,
stage I), (bottom left) invasive ductal carcino a (TN, grade 3, stage IIA), (botto right) lymph nodes
metastases from pati nts w th vasive ductal car inoma. (B) Western blot of LYPD3 expression in 50 µg
protein extracted from the cell lysate (left hand panel) or secretome (right hand panel) of MDA-MB-468
cells following treatment demonstrated an upregulation of LYPD3 protein following treatment with
norepinephrine or isoproterenol alone and also following concomitant treatment with ICI118,551.
(C) LYPD3 gene expression level in MDA-MB-468 cells following treatment demonstrates a significant
upregulation of LYPD3 in norepinephrine and isoproterenol stimulated MDA-MB-468 cells. Results
shown are the mean ± standard deviation. Statistical analysis was performed using an un-paired
Student’s T-test. * p < 0.05, ** p < 0.01. (D) LYPD3 gene expression levels (relative to the house keeping
Biology 2020, 9, 39 11 of 25
gene—HKG) in a panel of normal human tissues illustrates low levels of expression in the majority of
essential tissues tested (lung, spinal cord, liver, heart) (E) Enriched GO biological processes (as defined by
David annotation tool) of differentially expressed proteins identified via the mass spectrometry analysis
within the top 50 strongest interactions as defined by network inference analysis. The normalised
protein expression values of each identified protein (cut-off above 50% confidence) within the untreated
and norepinephrine treated cohorts (both lysate and secretome) were subjected to a network inference
analysis. In the network, the 50 strongest interactions (based on their absolute values) between any of the
proteins (defined by their strength of interaction) were selected and submitted to the David annotation
tool and as observed the top pathways identified were those associated with cell proliferation, migration,
adhesion and cell signalling. (F) LYPD3 gene expression levels in a panel of breast cell lines (relative to
the house keeping gene—HKG) showing that the more mesenchymal cell lines (MDA-MB-231 and
BT-549) express negligible levels of LYPD3 compared to the more epithelial cell lines (MDA-MB-468,
MDA-MB-453) with MCF-7 cells demonstrating the highest level of expression. Subsequently, the level
of LYPD3 expression in MCF-7 cells could be reduced by the incorporation of LYPD3 specific shRNA
to 26.4% of its original levels. (G) The effects of LYPD3 gene knockdown on the migration of MCF-7
breast cancer cells showed a significant reduction in the migration of MCF-7 vehicle cells following
norepinephrine stimulation (p = 0.0065). There was also a reduction in the migration of MCF-7 cells
following LYPD3 shRNA knockdown compared to shControl (p = 0.0054). All assays were performed in
triplicate (n = 3). Results shown are the mean ± standard deviation. Statistical analysis was performed
using an ANOVA test (Dunnett’s multiple comparison test). * p < 0.05, ** p < 0.01.
2.5. LYPD3 Knockdown Significantly Reduces the Migration of MCF-7 Cells In Vitro
The levels of LYPD3 in the lysate and secretome of MDA-MB-468 cells was measured following
adrenergic receptor stimulation and subsequent blocking with a β2-specific antagonist (Figure 3B).
LYPD3 protein expression was increased in norepinephrine (p = 0.0375) and isoproterenol (p = 0.0234)
stimulated cells with a subsequent decrease observed following treatment with an ADRβ2 antagonist
(Figure 3C). LYPD3 mRNA expression levels were low in normal tissues (Figure 3D) and when the
significantly associated proteins identified in the mass spectrometry analysis of MDA-MB-468 cell
lysates and secretome were subjected to network inference and subsequently altered pathways were
identified via the David annotation tool, it could be observed, as expected, that the most significant
pathways were associated with cell proliferation, migration and adhesion (Figure 3E and Supplementary
Materials Table S1A). The expression of LYPD3 in breast cancer cell lines varied with MCF-7 cells
expressing the highest levels. This expression could be knocked down to 26.4% of its basal level using
a LYPD3 specific shRNA (Figure 3F). MCF-7 cells were transfected with vehicle alone, shControl or
shLYPD3 and stimulated with or without norepinephrine for 24 h to induce cell migration. Following
norepinephrine treatment, cell migration significantly increased in MCF-7 vehicle cells (p = 0.0072) and
shControl (0.0268) but not in the shLYPD3. The increase in migration observed in MCF-7 vehicle cells is
more than originally observed (Figure 2B) and this could be due to two factors; a lower concentration of
norepinephrine was used to stimulate the cells (100 nM vs. 10 µM) and the cells used in the knockdown
studies were of a slightly lower passage number (passage 5 vs. passage 8). The difference in cell
migration observed between the norepinephrine stimulated vehicle only cells and the shControl cells
was not statistically significant (p = 0.1142).
In addition, shLYPD3 knockdown of norepinephrine stimulated MCF-7 cells caused a significant
decrease in migration compared to vehicle alone cells (p = 0.0065) and shControl cells (p = 0.0016).
Furthermore, in unstimulated cells there was a significant decrease in cell migration of shLYPD3
compared to shControl (0.0054) and vehicle treated cells (0.0188) (Figure 3G and Supplementary
Materials Figure S5). These results indicate that cell migration may be influenced by LYPD3 acting via
ABRβ signalling pathways.
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2.6. Elevated Levels of LYPD3 mRNA Are Present in Malignant Disease Compared to Their Non-Malignant
Counterpart in Several Cancers
Although previous studies have shown that LYPD3 is expressed in malignant tissues [20–22],
a comprehensive screen of recent mRNA expression data has, to the best of our knowledge, not
been performed. In our analysis we screened all cancers for the comparative mRNA expression
levels between malignant and normal counterparts using GEPIA [23]. Our analysis revealed that
in seven cancers (breast, cervical squamous cell carcinoma and endocervical adenocarcinoma, lung
adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma, testicular germ cell
tumours and thymoma) there is a significant (p < 0.001) over-expression of LYPD3 in the malignant
tissue versus the normal counterpart (Figure 4). This suggests that LYPD3 could be a potential
therapeutic target in multiple different cancers, and is not solely restricted to breast, oesophageal,
pancreatic and lung carcinomas.Biology 2020, 9, x FOR PEER REVIEW 13 of 25 
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3. Discussion
Early population studies reported an association between beta-blocker use and survival in
patients with breast cancer [10–12]. The proposed physiological mechanism involved inhibition of
β-adrenoceptor-activated cancer cell signalling pathways [8,19,23–31], resulting in a reduction of
metastasis [9,32,33]. Specific mediators implicated downstream of this process have, to our knowledge,
not been identified. Furthermore, the influence of adrenergic ligands on cell migration in vitro have
been controversial [7–9]. We found that two of the non-stimulated triple-negative basal-type breast
cancer models, MDA-MB-231 and MDA-MB-468, showed significantly raised levels of β2-adrenoceptor
gene and protein expression compared to the oestrogen responsive cell line. Although a challenge
with a non-selective ADRβ2 agonist confirmed functional adrenoceptors in all four cancer cell lines,
the strongest response was seen in MDA-MB-231 and MDA-MB-468, as evidenced by increased cAMP.
Although laboratory evidence supporting a clinical use for the beta-blocker propranolol in breast
oncology is strong, it has not been universal, in that propranolol is reported by some to increase
the proliferation of basal-type MDA-MB-231 breast cancer cells [34–37], but not by others [19,38].
We did not demonstrate a significant increase in survival in the breast cancer cells in response to
a selective β2-adrenoceptor antagonist (ICI-118,551). A recent orthotopic mouse model of basal-type
MDA-MB-231 breast cancer concurred that propranolol does not reduce primary tumour growth, but
instead reduces the number and size of metastatic tumours [9]. In summary, beta-blockers appear not
to be cytotoxic per se, but when combined with paclitaxel chemotherapy they appear to enhance its
effectiveness, as demonstrated in a mouse basal-type (MDA-MB-231) breast cancer model [27].
Herein, the association between ADRβ2 expression and key characteristics involved in metastasis
was assessed in four breast cancer models, including cell migration, adhesion and invasion. Migration
assays confirmed that the agonist norepinephrine increased the migration of MDA-MB-468, BT-549 and
MCF-7 cells, which was abrogated by the ADRβ2 antagonist ICI-118,551. In contrast, norepinephrine
reduced the migration of MDA-MB-231 cells, and ICI-118,551 increased their migration, as has been
reported by Carrie and Sebti [19]. However, when grown on collagen-1 or fibronectin protein-coated
plastic or synthetic membranes coated with basement membrane protein, MDA-MB-231 cells showed
a similar migratory behaviour to the other models (data not shown), thereby supporting the
findings of others [8,39,40]. In addition, two basal-type cell lines (MDA-MB-231, MDA-MB-468)
and the ER-positive MCF-7 cells exhibited increased norepinephrine-induced invasive behaviour
that was abrogated by the ICI-118,551 antagonist. These findings suggest ADRβ2 mediated
cellular pathways could be influenced by cell adhesion molecules [41], and may explain anomalous
behaviour reported for the MDA-MB-231 cancer model when grown on different surfaces. This
is further supported by the identification of proteins involved in cell adhesion, proliferation and
migration following a mass spectrometry analysis of MDA-MB-468 cell lysates and secretome after
ADRβ2 agonism/antagonism. The differences in migration observed between the MDA-MB-468 and
MDA-MB-231 cells could, in part, be explained by differences in signalling arising because MDA-MB-468
cells are of epithelial origin (i.e., pre-epithelial-mesenchymal transition EMT), whilst MDA-MB-231
cells possess a mesenchymal-like phenotype (post-EMT). In MDA-MB-468 cells, norepinephrine
could be signalling to initiate the acquisition of a more motile cell phenotype that would allow the
cancer cells to spread, whereas in the MDA-MB-231 cells the presence of norepinephrine in the
tissue microenvironment would signal that there is a favourable environment present for the cancer
cells to successfully colonise and establish a secondary tumour/metastatic lesion [42–45]. Literature
also demonstrates that catecholamines can both protect cancer cells from apoptosis [33] as well as
providing an advantageous environment whereby secondary tumours often become established
at catecholamine-producing tissues such as the brain and adrenal glands [46]. Furthermore, we
hypothesise that the opposing influence of adrenergic stimulation on cell migration of MDA-MB-468
and MDA-MB-231 cell lines could be linked to ADR heterodimerisation. Lavoie et al. showed that
heterodimerisation of ADRβ1 and ADRβ2 prevented agonist-induced internalisation of ADRβ2 [47]
and in our study we demonstrated that MDA-MB-468 cells expressed higher levels of the ADRβ1
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receptor than MDA-MB-231 cells. Furthermore, pharmacological diversity could be introduced via
heterodimerisation leading to differential desensitisation, changes in cell surface receptor expression
and alterations to the functionality of ADR subtypes [48–53].
Clearly there are many conflicting results in the literature for the two-dimensional migration of
MDA-MB-231 cells and its variants [7,8,11,36,42]. There are a number of plausible reasons behind
the differing results observed between the reports in the literature; including, the differing passage
numbers of cells, different sources of the cell lines, the different methods and conditions used in
performing the assays as well as time spans of the experiments. In addition, other reasons could
be: (i) differing levels of β2-adrenoceptor signalling capacity in relation to the differing levels of β2
adrenoceptor expression and (ii) differing dose-dependent downstream signalling behaviours of the
cell lines, including cAMP signalling. Not unsurprisingly, when the GO biological processes associated
with the treatment of MDA-MB-231 cells with norepinephrine was investigated in our proteomic study,
a number of genes associated with the following pathways were identified; proliferation, migration,
adhesion, negative regulation of the apoptotic process and membrane organisation (Supplementary
Materials Table S1B). Furthermore, Madden et al. has also shown that MDA-MB-231 cells can possess
an impaired cAMP signalling, with cAMP levels remaining high after stimulation by forskolin, which
could have profound effects and could possibly be a reason for the observed differences with this cell
line [28]. In addition, Pon et al. demonstrated that the parental MDA-MB-231 cell line does not possess
the feedforward Ca2+/cAMP loop and therefore has low levels of cAMP production and a delayed
response to stress [25].
Furthermore, Kim et al. and Choy et al. used different variants of the parental MDA-MB-231
cell line, which could have profound influence on the in vitro behaviour of the cells in response to
external stimulants such as isoproterenol [8,42]. Indeed, Pon et al. showed that the highly-metastatic
variant of the MDA-MB-231 cell line, MDA-MB-231HM are more responsive to β-adrenergic signalling
than the parental MDA-MB-231 cell line and this is reflected in the limited cAMP signalling observed
in the parental MDA-MB-231 cells compared to the high metastatic MDA-MB-231HM variant [25].
The two-dimensional migratory activity of MDA-MB-231 cells in response to isoproterenol has also
been assessed on different extracellular matrix (ECM) protein surfaces where again, opposing effects
were observed, even on the same surface, adding to the conflicting results of this cell line in the
literature [26,43].
We report that the strongest association between high ADRβ2 expression and cell behaviours
indicative of tumour aggression exists in two triple-negative basal-type breast cancer models
(MDA-MB-231, MDA-MB-468). Moreover, we have identified distinctly different protein profiles
between the two models in response to ADRβ2 activation, with differential expression of the
pro-metastasis protein LYPD3 observed in MDA-MB-468 cells following ADR stimulation and/or
ADRβ2 antagonism/inverse agonism. Stimulation of MDA-MB-468 cells with norepinephrine or
isoproterenol increased the levels of LYPD3 within the cell lysate, and was also secreted in the media.
Treatment with the antagonist ICI-118,551 reduced LYPD3 expression to a lower level than that observed
following norepinephrine/isoproterenol stimulation both in the lysate and secreted into the media.
LYPD3 is a glycosyl-phosphatidyl-inositol (GPI) anchored glycoprotein whose expression, we have
confirmed, is highly restricted in normal tissues [54,55]. Studies have also demonstrated a strong
association with a poor prognosis [20,22,56–58] and even though its expression has been observed in
breast cancer both in this study and in other published studies [21,59], its influence on tumourigenesis
is yet to be elucidated although our patient tumour microarray (TMA) data suggests that LYPD3 is
exclusively expressed in primary breast cancer and metastatic cases, with no expression observed in
normal breast tissue. Furthermore, our in silico analysis has revealed that LYPD3 may be a therapeutic
target in multiple cancer types, some of which have not been reported in the literature (testicular
germ cell tumours and thymoma). Interestingly, upregulation of LYPD3 has been observed following
cellular stress [60], however, this is the first study showing that treatment of breast cancer cells with
the endogenous stress hormone norepinephrine, can also lead to elevated LYPD3 levels.
Biology 2020, 9, 39 15 of 25
In MDA-MB-468 cells, treatment with the non-selective ADRβ agonist, isoproterenol, unregulated
LYPD3, whereas ICI-118,551, a selective ADRβ2 antagonist, reduced norepinephrine-induced LYPD3
expression and, when administered alone, reduced LYPD3 levels to that below the basal expression.
This would suggest, through a mechanism yet to be elucidated, that LYPD3 is regulated via the
ADRβ2 signalling pathway. In oesophageal cancer, LYPD3 is regulated via CREB (cAMP response
element binding protein) transcription co-activator signalling [61], and therefore, it is postulated that
norepinephrine regulates LYPD3 through an ADRβ2/cAMP/PKA/CREB/LYPD3 effector pathway [45].
In this pathway a conformational change in ADRβ2 would be induced following binding of
norepinephrine, mediating activation of the Gsα protein subunit. Following activation, Gsα can
then stimulate the adenylyl cyclase-induced conversion of adenosine triphosphate (ATP) into cAMP,
resulting in protein kinase A (PKA) activation. Downstream this would enable phosphorylation of
CREB via PKA, thereby inducing the transcriptional upregulation of LYPD3, and hence, increasing
cell migration [45,61]. In this study we have demonstrated the importance of LYPD3 in breast cancer
cell migration by successfully knocking down the expression of LYPD3 using LYPD3-specific shRNA.
We found that cell migration, measured using transwell migration assays, was significantly reduced
following shLYPD3 compared to shControl.
In the secretome of MDA-MB-468 cells, increased levels of LYPD3 and decreased levels of
LAMC1 (Laminin Subunit Gamma 1) were also observed following treatment with norepinephrine
and isoproterenol. This is an interesting observation because it is thought that LYPD3 can be cleaved
from the cell surface by ADAM Metallopeptidase Domain (ADAM)-10 and -17 and this shedding
can be induced by hypoxia [62]. To speculate, once LYPD3 has been shed, it may still be able to
bind laminin, via associating with the α6β4 integrin and matrix metallopeptidase-14 (MMP-14) and
contribute towards its fragmentation and the observed decrease in LAMC1 that we observed in our
proteomic analysis [60,63]. Alternatively, like its structural homologue urokinase-type plasminogen
activator receptor (uPAR), shed-LYPD3 could function as a chemoattractant [64].
In MDA-MB-231 cells, LYPD3 was not detected in the library of proteins generated from either the
lysate or the secretome and this observation was confirmed by gene expression analysis of LYPD3 in
a range of breast cell lines illustrating that MDA-MB-231 cells do not express LYPD3 at the mRNA level.
LYPD3 was expressed at negligible levels in the BT-549, which is also a cell line of mesenchymal origin.
Higher levels of expression of LYPD3 were observed in the epithelial-derived cell lines suggesting
that LYPD3 expression may correlate with EMT. Furthermore, Harner-Foreman et al. published
a spontaneous model of prostate cancer [65] and unpublished mass spectrometry proteomic profiling
data from this study revealed that LYPD3 was downregulated post-EMT. This is further supported by
observations made by Oshiro et al., where significant associations were made between LYPD3 and
EMT in both colorectal cancer cell lines and in clinical samples [66].
4. Materials and Methods
4.1. Cell Lines
The following breast cancer cell lines were purchased from the American Tissue Culture Collection
(ATCC): BT-549 (HTB-122™), ductal carcinoma; MCF-7 (HTB-22™), adenocarcinoma; MDA-MB-231
(HTB-26™), adenocarcinoma; MDA-MB-468 (HTB-132™), adenocarcinoma (Atcc.org, 2013). Breast
cancer cell lines were cultured in DMEM (Dulbecco’s Modified Eagle Medium) (Lonza, Slough,
UK) containing 10% v/v FCS (foetal calf serum) (GE Healthcare Life Sciences, Buckinghamshire,
UK). All cells were grown at 37 ◦C, in a humidified atmosphere with 5% v/v CO2. After washing
in PBS (phosphate-buffered saline), breast cancer cells were harvested using Trypsin and EDTA
(ethylenediaminetetraacetic acid)l (Lonza, Slough, UK).
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4.2. RNA Extraction, cDNA Synthesis and qRT-PCR
RNA was extracted using an RNeasy mini kit (QIAGEN, Manchester, UK), then quantified
on a NanoDropTM 8000 Spectrophotometer. cDNA synthesis was performed using MMLV-reverse
transcriptase (Promega, Southampton, UK) and oligo-dT primers (Promega, Southampton, UK). In
brief, 1 µL oligo(dT)15 primer (Promega, Southampton, UK) was annealed to 2 µg of RNA. After being
denatured for 5 min at 70 ◦C, a master mix solution was added, which contained: 0.7 µL Recombinant
RNasin® Ribonuclease Inhibitor (Promega, Southampton, UK); 1 µL Moloney-Murine Leukemia
Virus (M-MLV) reverse transcriptase (Promega, Southampton, UK); 5 µL M-MLV 5× reaction buffer
(Promega, Southampton, UK); 1 µL Deoxynucleotide Triphosphate Solution Mix (Sigma, Dorset, UK)
and 2.3 µL nanopure water. The samples were incubated for 60 min at 37 ◦C and then heated for 5 min
at 95 ◦C. cDNA was then stored at −20 ◦C.
Semi-quantitative real-time PCR was performed using SYBR® Green (Bio-Rad, Watford, UK)
chemistry and gene-specific primers (MWG Eurofins, Ebersberg, Germany) (Supplementary Materials
Table S2) on a Rotor-Gene 6000 real-time PCR cycler (QIAGEN, Manchester, UK). PCR reactions were
performed in 0.1 mL strip tubes containing a 12.5 µL mixture of: SYBR® Green (Bio-Rad, Watford, UK);
nanopure water; gene-specific primers (MWG Eurofins, Ebersberg, Germany) at a concentration of
5 pmol; and either 0.5 µL of cDNA or nanopure water (control). The following cycling conditions were
used (35–40 cycles): initial 5 min at 95 ◦C for enzyme activation, followed by denaturation at 95 ◦C for
10 s, annealing for 15 s at the primer–specific Tm (Supplementary Materials Table S2), and extension
at 72 ◦C for 20 s. Following each PCR the melt curves were examined prior to data analysis. Using
the Rotor-Gene Q Software and a threshold of 0.08, each transcripts Ct (cycle threshold) value was
determined in triplicate. The relative expression of each target gene was then semi-quantified using
the 2−∆∆CT method.
4.3. Flow Cytometry
Unconjugated antibodies were fluorescently labelled using Lightning-Link® (Innova Biosciences,
Cambridge, UK), according to the manufacturer’s protocol: ADRα1B antibody with PE-Cy7™; ADRα1D
antibody with APC (Allophycocyanin) and β2-adrenoceptor antibody with RPE (R-Phycoerythrin).
Harvested cells (1 × 105) were washed, pelleted and re-suspended in medium. Cells were then treated
with an Fc receptor blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) diluted in PBS
(10 min, 4 ◦C). Cells were incubated in the dark (30 min, 4 ◦C) with conjugated ADR antibodies (at
a pre-optimised concentration) (Supplementary Materials Table S3) and viable cells were identified
using LIVE/DEAD™ fixable violet dead cell stain (Thermo Fisher Scientific, Leicester, UK). Cells
(minimum 10,000) were analysed by flow cytometry (Beckman Coulter Gallios™, Kaluza™ software).
4.4. cAMP Signalling
Cells were treated with the non-selective β-agonist isoproterenol (1 µM, 10 min) and cAMP
production measured using the cAMP ParameterTM ELISA kit (R&D Systems, Minneapolis, MN,
USA). IBMX was incorporated to prevent cAMP degradation and phosphodiesterase activity on
cAMP production.
4.5. Cellular Survival
Cells were seeded at 5000 cells/well in 100 µL of advanced DMEM containing 2% FCS and 4 mM
L-glutamine. The cells were incubated at 37 ◦C, 5% CO2 in a humidified atmosphere for 24 h. After
24 h the media was carefully removed and the cells washed once with PBS. Fresh serum-free advanced
DMEM was added to each well and the cells serum-starved for 24 h. After 24 h, the media was removed
and the cells washed with PBS. 100 µL of advanced DMEM containing 2% FCS and 4 mM L-glutamine
was adding to the wells with or without the addition of ICI-118,551 (β2-ADR selective antagonist,
Sigma, Dorset, UK) (concentration range 1 pM–10 µM). Cells were treated with antagonists for 30 min
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prior to the addition of 10 µM norepinephrine (Sigma, Dorset, UK) for 72 h at 37 ◦C in a humidified
atmosphere containing 5% CO2. After 72 h, 100 µL of 2× detection reagent was added to each well and
the plate incubated for 60 min. The plate was then read using a Tecan Ultra fluorescent plate reader
(Tecan Ultra, Mannedorf, Switzerland; excitation 485 nm, emission 535 nm).
4.6. Adhesion Assays
Cells were resuspended in 10 mL of serum-free media at 200,000 cells/mL in a falcon tube and were
incubated for 30 min to allow recovery from detachment. 10 µM ICI-118,551 was added to the cells for
30 min prior to the addition of norepinephrine (at pre-optimised concentrations). 50 µL of serum-free
media containing norepinephrine or media alone was added to each well of the 96-well plate and
the plate was incubated for 30 min. After 30 min, 10,000 cells/well of cell suspension was added to
each well of the 96-well plate [96-well plates pre-coated with human fibronectin (1.0 µg/well), human
vitronectin (0.5 µg/well) (R&D Systems, Minneapolis, MN, USA), or collagen I (3 mg/mL) (Thermo
Fisher Scientific, Leicester, UK)]. Untreated cells were added to wells containing 50 µL of pre-incubated
media containing DMSO. Treated cells were added to wells containing 50 µL of pre-incubated media
containing 10 µM norepinephrine. The plate was then incubated for 3 h at 37 ◦C in a humidified
atmosphere containing 5% CO2. The media was removed from each well and the cells washed carefully
twice with PBS. The final PBS wash was aspirated, the cells fixed with 4% paraformaldehyde in PBS
and the plate incubated at room temperature for 20 min. The wells were washed twice with PBS. Cells
were stained by adding 50 µL of crystal violet/cell stain solution and incubated at room temperature
for 15 min. Wells were washed twice with deionised water and the last wash aspirated. The wells were
allowed to fully dry at room temperature. Once dry, the wells of the plates were scanned using a C.T.L.
ELISPOT plate reader and the number of remaining cells counted using ImmunoSpot® software
(ImmunoSpot, Bonn, Germany).
4.7. Cultrex® Cell Migration Assay
Cells were serum-starved for 24 h prior to performing the assay. 1 × 106 cells/mL in serum-free
media (MDA-MB-231, BT-549) or 0.5% FCS containing media (MDA-MB-468, MCF-7) were added to
a 1.5 mL microtube along with 10 µM ICI-118,551. 50 µL/well of cell suspension (50,000 cells) with or
without antagonists was added to the top chamber of the plate followed by the addition of 150 µL
of DMEM containing 10% FCS to the bottom chamber of each well. The cells were incubated for
30 min prior to the addition of norepinephrine (10 µM). The plate was incubated for 24 h at 37 ◦C in
a humidified atmosphere containing 5% CO2. After incubation, the top chamber was inverted and
carefully shaken to remove the culture medium and transferred to the black receiver plate. Each well
of the top chamber was washed with 100 µL of warm 1×wash buffer and the top chamber inverted
and carefully shaken to remove excess wash buffer and placed back into black receiver plate. To the
bottom chamber of each well is added 100 µL of 1000× cell dissociation solution/ Calcein AM solution
and the plate incubated at 37 ◦C in a humidified atmosphere containing 5% CO2 for 60 min. The plate
was read on a fluorescent plate reader at 485 nm excitation, 520 nm emission (Tecan Ultra, Mannedorf,
Switzerland).
4.8. CultreCoat® Medium BME Cell Invasion Assay
Cells were serum-starved for 24 h prior to performing the assay. 1 × 106 cells/mL in serum-free
media (MDA-MB-231, BT-549) or 0.5% FCS containing media (MDA-MB-468, MCF-7) were added to
a 1.5 mL microtube along with 10 µM ICI-118,551. 25 µL/well of cell suspension (25,000 cells) were
added to the top chamber of the plate followed by the addition of 150 µL of DMEM containing 10% FCS
to the bottom chamber of each well. The cells were incubated for 30 min prior to the addition of 10 µM
norepinephrine. The plate was incubated for 24 h at 37 ◦C in a humidified atmosphere containing
5% CO2. After incubation the top chamber was washed with 100 µL of warm 1× wash buffer and
placed into a black receiver plate. To the bottom chamber of each well 100 µL of 1000× cell dissociation
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solution/Calcein AM solution is added and the plate incubated at 37 ◦C in a humidified atmosphere
containing 5% CO2 for 60 min to fluorescently label and dissociate cells from the membrane. After
60 min, the top chamber was removed and fluorescence was measured using a plate reader (Tecan
Ultra, Mannedorf, Switzerland; 485 nm excitation, 520 nm emission).
4.9. Proteomic Analysis
MDA-MB-231 (1.3 × 106) and MDA-MB-468 (1.2 × 106) cells were seeded and grown to 90%
confluency. On the day of treatment 1 mM stocks of norepinephrine, isoproterenol and ICI-118,551 were
made up in serum free DMEM and passed through a 0.22 µm filter prior to serial dilution. Media was
removed from each flask, and cells were washed three times with PBS. Untreated cells received 25 mL
of serum free DMEM, and treated cells received 25 mL of DMEM containing 10 µM of the appropriate
treatment condition. After 30 min incubation 10 µM norepinephrine or 10 µM isoproterenol was added
into the relevant flasks. Flasks were then incubated at 37 ◦C, 5% CO2 for 24 h. Twenty four hours after
treatment secretome samples were obtained by removing the media and centrifuging (300× g, 5 min),
filtered (0.22 µm) and concentrated using Amicon Ultra-15 Centrifugal Filter Units (Merck, Kenilworth,
NJ, USA). Cell lysates were prepared using 9.5 M urea (Melford, Stowmarket, UK)/2% v/v dithiothreitol
(Melford, Stowmarket, UK)/1% v/v n-octyl-beta-glycopyranoside (Apollo Scientific Limited, Stockport,
UK) containing protease inhibitor (Sigma, Dorset, UK). The lysates were harvested, chilled on ice for
5 min, sonicated for 5 min and this process was repeated three times before centrifugation for 10 min at
12,000× g and storage at −80 ◦C.
Cell lysate (100 µg) and secretome (100 µg) were diluted in 50 mM tri-ethyl ammonium bicarbonate
(TEAB) before reduction (5 mM DTT at 56 ◦C for 20 min) and alkylation (15 mM iodoacetamide at
room temperature for 15 min) and then digested for 16 h using Trypsin/Lys-C (Promega, Southampton,
UK) at 37 ◦C at a 20:1 protein:protease ratio (w/w) in a thermomixer (650 rpm) [67]. Next, samples
were cleaned up using HyperSep C18 cartridges (Thermo Scientific, Leicester, UK) for solid phase
extraction. A vacuum concentrator was then used to concentrate the samples before resuspension in 5%
acetonitrile + 0.1% formic acid and subsequent analysis of the peptides on an AB Sciex TripleTOF 5600+
MS/MS instrument in both SWATH (Sequential Window Acquisition of All Theoretical Mass Spectra)
and IDA (information dependent acquisition) acquisition modes (Sciex, Framingham, MA, USA).
4.10. Mass Spectrometry
Each sample was analysed on a Sciex TripleTOF 5600+ mass spectrometer coupled in line with
an Eksigent ekspert nano LC 425 system running in micro flow (5 µL/min) mobile phase B (100%
acetonitrile + 0.1% formic acid) over mobile phase A (0.1% formic acid). In brief, 8 µg of sample was
injected and trapped onto a YMC Triart-C18 pre-column (5 mm, 3 µm, 300 µm ID) at a flow rate of 10 µL
min for 2 min. The sample was then eluted off the pre-column and onto a YMC Triart-C18 analytical
column (15 cm, 2 µm, 300 µm ID) that was in line with the Sciex TripleTOF 5600+ Duospray Source
using a 50 µm electrode in positive mode, +5500V. The following linear gradients were used: for
SWATH, mobile phase B increasing from 3% to 30% over 38 min, 30% to 40% over 5 min, 40% to 80%
over 2 min for wash and re-equilibration (total run time 57 min). For IDA, mobile phase B increasing
from 3% to 30% over 68 min, 30% to 40% over 5 min, 40% to 80% for column wash and re-equilibration
over 2 min (total run time 87 min). Data independent acquisition was performed using 100 variable
SWATH windows (optimised on sample type) (TOFMS m/z 400-1250) 25 ms accumulation time; 2.6 s
cycle and IDA with a top 30 ion fragmentation (TOFMS m/z 400-1250) followed by 15 s exclusion using
rolling collision energy, 50 ms accumulation time; 1.8 s cycle.
Spectral library generation, alignment and fold change analysis were performed as described
previously [68]. In brief, IDA data were searched using ProteinPilot 5.0 (iodoacetamide alkylation,
biological modifications emphasised in a thorough search) against the Swiss-Prot human database (June
2017). The Sciex OneOmics software was used to analyse the SWATH data following extraction against
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the locally generated library with the following parameters; 12 peptides per protein, six transitions per
peptide, XIC width 30 ppm, 6 min retention time window.
4.11. LYPD3 Protein Expression
Mass spectrometry and curated protein profiling of the two basal-type cell lines (MDA-MB-231
and MDA-MB-468) identified increased LYPD3 expression, a pro-metastasis protein. LYPD3 protein
expression in breast cancer tissue was confirmed by immunostaining three wax-embedded TMA slides
(BC081120b, BC10010d, BR1201) comprising 260 cases of invasive ductal adenocarcinoma, 50 cases of
metastatic adenocarcinoma and 10 cases of normal breast tissue (U.S Biomax, Rockville, MD, USA).
Sections were immunostained using a monoclonal rabbit anti-human LYPD3 antibody
(Supplementary Materials Table S3) on a BenchMark ULTRA stainer (Ventana Medical System,
Inc, Oro Valley, AZ, USA) with ultraView Detection Kit (Ventana Medical, Oro Valley, AZ, USA).
The intensity of LYPD3 immunostaining was microscopically assessed for cytoplasmic staining
using a five-point scoring technique, where a score of 0 represented nil staining; a score of 1: weak; 2:
moderate; 3: strong; 4: strong cytoplasmic staining with additional cell membrane staining.
The association between LYPD3 expression and clinical variables in malignant adenocarcinoma,
metastasis and adjacent normal breast tissue was statistically tested using SPSS (Version 24, IBM, UK).
Immunohistochemistry scores were dichotomously categorised (0, 1 = negative; 2, 3, 4 = positive) for
Chi-square tests. Significance levels were p = 0.05 or less.
4.12. Western Blot
Total cell lysates were used from the proteomic analysis. In brief, 50 µg of total protein from each
sample was prepared with sample reducing buffer (60 mM Tris-HCl (pH 6.8), 2% SDS (sodium dodecyl
sulphate), 10% glycerol and 0.01% bromophenol blue) at a ratio of 1:3 sample vs. reducing buffer.
The sample was resolved on an SDS gel (10% resolving gel, 5% stacking gel) with Tris/glycine/SDS gel
running buffer (Geneflow) at a constant voltage of 150 V. After separation, samples were transferred
onto nitrocellulose membranes using Tris/glycine/methanol transfer buffer at a constant current of
180 mA for 75 min at 4 ◦C. Membranes were blocked in 10% Marvel™ dried skimmed milk powder for
1 h before being probed with rabbit anti-LYPD3 antibody (1:1000, ab151709, Abcam, Cambridge, UK),
rabbit anti-beta 2 adrenergic receptor antibody (1:1000, ab182136, Abcam, Cambridge, UK) and rabbit
anti-beta actin antibody (1:5000, ab8227, Abcam, Cambridge, UK) overnight at 4 ◦C. The membranes
were then washed and goat anti-rabbit IgG HRP-linked antibody was added (1:1000, Cell Signalling
Technology, London, UK). Membranes were washed and exposed to the Clarity Western ECL Substrate
(1:1) and imaged using a Syngene G:Box and Genesys v1.5.4.0 software (Syngene, Cambridge, UK).
4.13. Generation of LYPD3 Knockdown Cell Line
Lentiviral shRNA plasmids and packaging mix (SHP001) were purchased from Sigma (Dorset,
UK): shLYPD3 (catalogue number: SHC204) and shControl (catalogue number: SHCLNV-NM_133743).
MCF-7 cells (2.5 × 105) were transfected with shRNAs and hexadimethrine bromide (Sigma, H9268) at
a final concentration of 8 µg/mL for 18 h. Resistant colonies were selected using media containing
2 µg/mL puromycin.
4.14. In Silico Gene Expression Profiling
LYPD3 gene expression profiling was performed using patient gene expression profiles generated
through The Cancer Genome Atlas (TCGA) [69] and the Genotype-Tissue Expression (GTEx) project [70]
and data was assessed via the Gene Expression Profiling Interactive Analysis (GEPIA) [23].
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5. Conclusions
For the first time, this study postulates that ADRβ2 signalling can regulate LYPD3. Furthermore,
by knocking down LYPD3 expression in the MCF-7 breast cancer cell line we demonstrated that LYPD3
supports both basal and norepinephrine-induced cell migration. Thus, its level of expression could be
an important indicator of breast tumour progression and this was supported by our findings in breast
cancer tissue cohorts. This highlights LYPD3 as a promising therapeutic target but also supports the
development of novel beta-blocker compounds that could be used prophylactically to try and reduce
metastatic spread.
Availability of Data and Materials: The mass spectrometry proteomics data that support the findings of this
study have been deposited to the ProteomeXchange Consortium [71] via the PRIDE partner repository [72] with
the dataset identifier PXD009488. All other data generated or analysed during this study are included in this
published article (and its supplementary information files).
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-7737/9/2/39/s1.
Figure S1: Survival of breast cancer cells in response to norepinephrine alone, ICI-118,551 alone or in combination
with norepinephrine. Cell survival was assessed after concomitant treatment with norepinephrine and ICI-118,551
and was found to be significantly increased in MDA-MB-468 (p < 0.01) and ER-positive MCF-7 breast cancer cells
(p < 0.05). No significant difference was seen in MDA-MB-231 and BT-549 cells. Figure S2: Adhesion of breast
cancer cells to fibronectin coated tissue culture plastic following norepinephrine treatment. (A,B) MDA-MB-468
cells, (C,D) MDA-MB-231 cells, (E,F) BT-549 cells and (G,H) MCF-7 cells. Norepinephrine increased the adhesion
of all breast cancer cell lines to a fibronectin coated surface. This was statistically significant in all cell lines at
the 0.1 µM and 0.001 µM concentrations. Furthermore, as the concentration on norepinephrine decreases the
adhesion of breast cancer cells to the fibronectin coated surface increases in all cell lines. Figure S3: Treatment
of breast cancer cells with ICI-118,551 and norepinephrine. Cell migration using a scratch assay was assessed
after concomitant treatment with norepinephrine and ICI-118,551. At the 10 µM ICI-118,551 concentration, cell
migration was significantly decreased in the MDA-MB-468, BT-549 and MCF-7 breast cancer cell lines (p < 0.01).
Figure S4: (A) Peptide sequences used for quantitation identified from the LYPD3 protein following NE/ISO vs.
UT treatment of MDA-MB-468 breast cancer cells and preparation of cell lysates. (B) Peptide sequences used for
quantitation identified from the LYPD3 protein following NE/ICI-118,551+NE vs. UT treatment of MDA-MB-468
breast cancer cells and preparation of cell secretome. Figure S5: 50 µg protein from the following samples was
analysed for LYPD3 protein expression using western blotting; (from left to right) MCF-7 vehicle alone, MCF-7
vehicle and norepinephrine, shControl alone, shControl alone and norepinephrine, shLYPD3 alone, shLYPD3
alone and norepinephrine. Table S1: Enriched GO biological processes for MDA-MB-468 and MDA-MB-231 cells
following norepinephrine stimulation. (A) MDA-MB-468 cells. (B) MDA-MB-231 cells. Table S2: Primer sequences
used for qRT-PCR. Table S3: Antibody details for FACS and immunohistochemistry. Table S4: Normalised MS
protein expression data for all identified proteins.
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Abbreviations
GPCR g-protein coupled receptor
qPCR polymerase chain reaction
MFI mean fluorescence intensity
FCS foetal calf serum
PFS progression free survival
ADRβ beta-adrenergic receptor
BME basement membrane extract
LCMS liquid chromatography mass spectrometry
SWATH-MS sequential window acquisition of all theoretical mass spectra
LYPD3 ly6/PLAUR domain-containing protein 3 precursor
TMA tumour microarray
cAMP cyclic adenosine monophosphate
NE norepinephrine
ISO isoproterenol
UT untreated
EMT epithelial to mesenchymal transition
GPI glycosyl-phosphatidyl-inositol
CREB cAMP response element binding protein
ATP adenosine triphosphate
PKA protein kinase A
LAMC1 laminin subunit gamma 1
MMP matrix metallopeptidase
uPAR urokinase-type plasminogen activator receptor
NE norepinephrine
SWATH Sequential Window Acquisition of All Theoretical Mass Spectra
IDA information dependent acquisition
HKG house keeping gene
ANOVA analysis of variance
EDTA ethylenediaminetetraacetic acid
SDS sodium dodecyl sulphate
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